Q32 Bio Inc (QTTB)

Generated: August 15, 2026

❌ Fail

Business Overview

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing therapies that target immune dysfunction, including programs in inflammatory and autoimmune disease. It does not appear to have a commercial product franchise yet, so its money comes primarily from collaboration/licensing revenue when available, research funding tied to development programs, and financing activities that support ongoing R&D and corporate overhead.

Non-Recurring Revenue

I did not find evidence of a material one-time revenue windfall in the most recent fiscal periods that would obviously distort reported operating performance. The available 2025 financial data show revenue of about $53.7 million, but the public snippets I found do not break that figure into recurring versus non-recurring components, so I cannot verify whether any large licensing payment or similar event was embedded in it.^[1]^[5] Because Q32 Bio is a biotech company and its income may be driven by collaboration milestones, investors should still inspect the 10-K revenue footnotes and “license and collaboration revenue” disclosures for any concentrated one-off inflow.^[7]

Short-Seller & Fraud Risk

Q32 Bio currently looks like a battleground stock. MarketBeat reported short interest of 2.26 million shares as of July 15, 2026, equal to 20.37% of the public float, which is above the rough 15% threshold in your screen.^[2] I did not find a dedicated short-seller report or a clearly documented fraud allegation in the results reviewed, and I did not find a publicly highlighted SEC or securities class-action issue in the last 12 months. Even without a formal fraud campaign, the short-interest level alone is enough to elevate trading risk materially.^[2]^[3]

Financial Health

The balance sheet does not look burdened by large debt. Public financial snippets indicate that long-term debt was not reported at fiscal 2025 year-end, and Q32 Bio had about $48.3 million in cash at year-end 2025.^[1]^[5] More importantly, the company said in May 2025 that its $65.5 million cash balance was expected to fund operations into 2H’26, and by June 30, 2026 it reported $106.3 million in cash after equity financing and full repayment of venture debt.^[6]^[9] That implies near-term refinancing pressure is currently low, and I did not find evidence of covenant distress or a credit downgrade.^[6]^[9]

Cyclicality Risk

Q32 Bio does not operate in a classic cyclical industry such as mining, autos, semiconductors, or shipping. Its results are driven mainly by biotech development milestones, research spending, and capital markets access rather than broad macro demand cycles. That means there is no obvious commodity-style boom/bust pattern or a clear indication that current revenue and margins are temporarily elevated relative to a normal business cycle. For investors, the larger risk is binary clinical and financing execution, not cyclicality.

Sources

Featured in MagicDiligence Analysis

Magic Formula Screen Update - August 15, 2026 August 15, 2026